Regulation of human bone sialoprotein gene transcription by platelet-derived growth factor-BB.
Platelet-derived growth factor (PDGF) is produced by mesenchymal cells and released by platelets following aggregation and is synthesized by osteoblasts. In bone, PDGF stimulates proliferation and differentiation of osteoblasts. PDGF also increases bone resorption, most likely by increasing the number of osteoclasts. Bone sialoprotein (BSP) is thought to function in the initial mineralization of bone, selectively expressed by differentiated osteoblast. To determine the molecular mechanisms PDGF regulation of human BSP gene transcription, we have analyzed the effects of PDGF-BB on osteoblast-like Saos2 and ROS17/2.8 cells. PDGF-BB (5 ng/ml) increased BSP mRNA and protein levels at 12 h in Saos2 cells, and induced BSP mRNA expression at 3 h, reached maximal at 12 h in ROS17/2.8 cells. Transient transfection analyses were performed using chimeric constructs of the human BSP gene promoter linked to a luciferase reporter gene. Treatment of Saos2 cells with PDGF-BB (5 ng/ml, 12 h) increased luciferase activities of all constructs between -184LUC to -2672LUC including the human BSP gene promoter. Effects of PDGF-BB abrogated in constructs included 2 bp mutations in the two cAMP response elements (CRE1 and CRE2), activator protein 1(3) (AP1(3)) and shear stress response element 1 (SSRE1). Luciferase activities induced by PDGF-BB were blocked by protein kinase A inhibitor H89 and tyrosine kinase inhibitor herbimycin A. Gel mobility shift analyses showed that PDGF-BB increased binding of CRE1, CRE2, AP1(3) and SSRE1 elements. CRE1- and CRE2-protein complexes were supershifted by CREB1 and phospho-CREB1 antibodies. Notably, AP1(3)-protein complexes were supershifted by c-Fos and JunD, and disrupted by CREB1, phospho-CREB1, c-Jun and Fra2 antibodies. These studies, therefore, demonstrate that PDGF-BB stimulates human BSP transcription by targeting the CRE1, CRE2, AP1(3) and SSRE1 elements in the human BSP gene promoter.
Mezawa
Masaru
M
Department of Periodontology, Nihon University School of Dentistry at Matsudo, Chiba, Japan.
Araki
Shouta
S
Takai
Hideki
H
Sasaki
Yoko
Y
Wang
Shuang
S
Li
Xinyue
X
Kim
Dong-Soon
DS
Nakayama
Youhei
Y
Ogata
Yorimasa
Y
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology*; D000818:Animals; D001483:Base Sequence; D000077214:Becaplermin; D045744:Cell Line, Tumor; D005786:Gene Expression Regulation; D006801:Humans; D058574:Integrin-Binding Sialoprotein; D008957:Models, Genetic; D008969:Molecular Sequence Data; D010006:Osteoblasts / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011401:Promoter Regions, Genetic; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D020218:Response Elements; D012795:Sialoglycoproteins / Q000235:genetics* / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*; D014162:Transfection
D043925:Angiogenesis Inducing Agents; C546871:IBSP protein, human; D058574:Integrin-Binding Sialoprotein; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D012795:Sialoglycoproteins; D000077214:Becaplermin